Withdraw due to duplicate registration. Clinical efficacy characteristics and safety evaluation of Suhexiang pills in the treatment of ischemic stroke multi-center registration study

Clinical efficacy characteristics and safety evaluation of Suhexiang pills in the treatment of ischemic stroke multi-center registration study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079654

Enrollment

Unknown

Registered

2024-01-09

Start date

2022-10-11

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Suhe Xiang pill group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: ? Age =18 years old; ? Hospitalized patients who met the diagnosis of acute ischemic stroke; ? Within 7 days of onset; ? Suhexiang pill treatment; ? The patient or legal representative shall give informed consent and sign the informed consent.

Exclusion criteria

Exclusion criteria: ? People who are known to be allergic to Suhe Xiang pills or the ingredients contained in them; ? Patients with other diseases that seriously affect the evaluation of neurological function and the evaluation of daily living ability; ? Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
mRS score;	—

Secondary

Measure	Time frame
NIHSS score;Barthel score;GCS score;Chinese medicine consciousness information collection table;	—

Countries

China

Contacts

Public ContactLai Xinxing

Dongzhimen Hospital, Beijing University of Chinese Medicine

new-star@163.com+86 159 0111 1280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026